SUBSCRIBETO WEEKLY E-NEWSLETTER SUBSCRIBETO INSIGHT NEWSPAPER STORY IDEAS? neilforbes@insightnews.com.au

PAST ISSUES

Browse through our past issues online. An exact copy of the print magazine with links to interesting websites and more.

image
image
image
image

 

NEWS NOW!

Sport accounts for 10% of children’s severe eye trauma: 12-year audit

Thursday, January 22, 2015

As children across Australia and New Zealand return to school in the coming weeks, parents and care-givers should be aware of the risk of paediatric eye injuries as school and sport resume, according to The Royal Australian and New Zealand College of Ophthalmologists. The Lions Eye Institute in Western Australia is currently working on a large research program to find solutions to prevent children’s eye injuries. As part of this research a 12-year audit was conducted of children’s eye injuries requiring admission to hospital in Perth, WA. That has led to a proposal for sports eye protection to be accepted for review by Standards Australia in late November last year. ...read more

Japan approves drug for myopic CNV

Thursday, January 22, 2015

The approvals, and the sales, just keep piling up for Eylea, the blockbuster that Bayer shares with developer Regeneron. A short time after receiving an important approval in Europe, it has won approval in Japan, the world’s third largest market, for use in myopic choroidal neovascularization (myopic CNV). Bayer has announced that the approval by Japan’s health ministry was based on positive data from the Phase III MYRROR study in myopic CNV in which patients’ vision improved markedly in 24 weeks. The drug manufacturer said that in Japan, pathologic myopia and the associated myopic CNV is the second-most-common cause of blindness.  ...read more

Ophthalmologist in United States overcharged Medicare by $11m

Thursday, January 22, 2015

Two medical practitioners – whose combined Medicare earnings in 2012 approached $US30 million ($A37 million), according to government payment data – have been accused of overbilling and fraud. Florida ophthalmologist Dr Salomon Melgen earned $20.8m ($A25m) from Medicare in 2012. A 2009 ruling found he overcharged Medicare by $US8.9m ($A11m) for multiple-dosing the injectable macular degeneration drug Lucentis (Ranbizumab). Lucentis is manufactured by a company that pays large rebates to doctors, according to The New York Times. Moreover, many ophthalmologists consider the cheaper drug Avastin as an appropriate equivalent to Lucentis. If Dr Melgen had used Avastin instead, his Medicare billings for the shots would have dropped from $11.8m to under $400,000. ...read more

Current Issue

CLICK ON THE COVER TO VIEW INSIGHT ONLINE

PLEASE CLICK ON THE COVER TO VIEW OUR 400th ISSUE.

© 2014 INSIGHT | PRIVACY POLICY